Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

0(0%)

Results Posted

100%(5 trials)

Terminated

1(11%)

Phase Distribution

Ph phase_2

33%

Ph phase_3

44%

Ph phase_1

22%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

2(22.2%)

Phase 2Efficacy & side effects

3(33.3%)

Phase 3Large-scale testing

4(44.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

55.6%

5 of 9 finished

Non-Completion Rate

44.4%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(4)

Detailed Status

Completed5

Withdrawn3

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (22.2%)

Phase 23 (33.3%)

Phase 34 (44.4%)

Trials by Status

completed556%

terminated111%

withdrawn333%

Recent Activity

0 active trials

Showing 5 of 9

completedphase_2

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

NCT01990209

completedphase_3

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

NCT01707966

completedphase_3

Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.

NCT01193257

withdrawnphase_3

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

NCT02053311

completedphase_1

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

NCT01666314

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT01990209Phase 2

Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)

Completed

NCT01707966Phase 3

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

Completed

NCT01193257Phase 3

Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer.

Completed

NCT02053311Phase 3

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Withdrawn

NCT01666314Phase 1

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

Completed

NCT01866423Phase 2

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Terminated

NCT01193244Phase 3

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Completed

NCT01658527Phase 2

TAK-700 in Castration Resistant Prostate Cancer

Withdrawn

NCT02054793Phase 1

Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)